KaloBios Pharmaceuticals Inc.’s stock will be suspended from the Nasdaq starting Jan. 13, Nasdaq Inc. said in a statement Tuesday. The trading halt on the drug company’s shares, which has been in place since Dec. 17, will no longer be in effect following the suspension, meaning they will be allowed to trade in the over-the-counter markets under the symbol KBIOQ. Nasdaq said a hearing to review KaloBios’s appeal of the delisting determination is scheduled for Feb. 25. Shares of KaloBios, which filed for bankruptcy on Dec. 30, were halted on Dec. 17 when majority owner Martin Shkreli was arrested on fraud charges.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News